WASHINGTON — The United States and United Kingdom announced a high-level agreement Monday under which the U.K. is expected to pay more for medicines.
In exchange for agreeing to increase payments going forward, the U.K. will be spared from pharmaceutical tariffs being considered by the Trump administration.
The announcement represents a crucial element of President Trump’s agenda to lower U.S. drug prices and to get other rich nations, which generally pay far less for medicines than the U.S., to pay more. The Trump administration has struck confidential deals with a handful of drugmakers to lower their prices in some U.S. plans, particularly Medicaid.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply